(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone
Morbid Obesity
Explore 61 assets in Morbid Obesity →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Cairo University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07337135CT.gov Opioid-Free vs Opioid-Based Anesthesia in Bariatric Surgery | — | Completed | — | — | — |
NCT05752799CT.gov Evaluation of the Stress Response in Bariatric Surgery With and Without the Use of Opioids | — | Recruiting | — | — | — |
NCT04576975CT.gov Ketamine Infusion vs Dexmedetomidine Infusion in Obese Patients Undergoing Bariatric Surgery | — | Unknown | — | — | — |
NCT04836819CT.gov Analgesia Management in Bariatric Surgery | — | Completed | — | — | — |
NCT03747094CT.gov Sedation of Morbidly Obese for Balloon Insertion | — | Unknown | — | — | — |
NCT01724983CT.gov Ketamine in Bariatric Surgery | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Morbid Obesity
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone (this asset) | Cairo University | P3 | B · 57 |
| Lidocaine | Instituto Mexicano del Seguro Social | P4 | BBB |
| Propofol | G.Gennimatas General Hospital | P4 | BBB |
| Chenodeoxycholic Acid | Hvidovre University Hospital | P4 | BBB |
| Colesevelam | Hvidovre University Hospital | P4 | BBB |
| Ramifentanyl | Hospital dos Lusíadas | P4 | BBB |
| Semaglutide | Zuyderland Medisch Centrum | P4 | BBB |
| Amoxicillin | Fatih Sultan Mehmet Training and Research Hospital | P4 | BBB |
| Omeprazole | Fatih Sultan Mehmet Training and Research Hospital | P4 | BB |
+42 more in the Morbid Obesity cohort
Other indications for (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Pain Syndrome | — | P4 | BBB · 74 |
| Post-Traumatic Stress Disorder | — | P4 | BBB · 74 |
| Depressive Disorder | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone in Morbid Obesity. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/2-o-chlorophenyl-2-methylaminocyclohexanone-morbid-obesity
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →